Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

Medical Oncology

Volumn 28, Issue 4, 2011, Pages 1140-1144

  Harmankaya, Kaan ^a   Erasim, Christa ^a   Koelblinger, Claus ^b   Ibrahim, Ramy ^c   Hoos, Axel ^c   Pehamberger, Hubert ^a   Binder, Michael ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

human chorionic gonadotropin; CTLA 4; Cytotoxic T lymphocyte antigen 4; Immune related adverse events; Immunotherapy; Ipilimumab; Melanoma

Indexed keywords

CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; METHYLPREDNISOLONE; PREDNISOLONE; ZOLEDRONIC ACID;

ADULT; ANOREXIA; ARTICLE; AUTOIMMUNE THYROIDITIS; BLURRED VISION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; COLITIS; COLON BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIARRHEA; DIPLOPIA; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG TREATMENT FAILURE; ERYTHEMATOSQUAMOUS EXANTHEMA; EYE PAIN; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; MYALGIA; NAUSEA; OSTEOPOROSIS; PRIORITY JOURNAL; RASH; SPLEEN METASTASIS; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; UVEITIS; VOMITING;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DIARRHEA; FATIGUE; FEMALE; HUMANS; MELANOMA; METHYLPREDNISOLONE; MIDDLE AGED; NAUSEA; SKIN NEOPLASMS; VOMITING;

EID: 84655165056     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9606-0     Document Type: Article

References (21)

1. S O'Day P Boasberg 2006 Management of metastatic melanoma 2005 Surg Oncol Clin N Am 15 419 437
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Jun 14 [Epub ahead of print].
3. JM Kirkwood AA Tarhini MC Panelli SJ Moschos HM Zarour LH Butterfield HJ Gogas 2008 Next generation of immunotherapy for melanoma J Clin Oncol 26 3445 3455
4. SS Agarwala 2009 Current systemic therapy for metastatic melanoma Expert Rev Anticancer Ther 9 587 595
5. L Fong EJ Small 2008 Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment J Clin Oncol 26 5275 5283
6. JD Wolchok B Neyns G Linette S Negrier J Lutzky L Thomas W Waterfield D Schadendorf M Smylie T Guthrie Jr JJ Grob J Chesney K Chin K Chen A Hoos SJ O'Day C Lebbé 2010 Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 155 164
7. J Weber JA Thompson O Hamid D Minor A Amin I Ron R Ridolfi H Assi A Maraveyas D Berman J Siegel SJ O'Day 2009 A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 5591 5598
8. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Feb 10. [Epub ahead of print].
9. O'Day S, Weber J, Lebbe C, Maio M, Pehamberger H, Harmankaya K, Siegel K, Hoos A, Humphrey R, Wolchok J. Effect of ipilimumab treatment on 18-month survival: update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol. 2009;27(Suppl. 15s); abstract 9033.
10. M Binder C Forstinger H Koelbl C Bieglmayer 1999 A 30-year-old woman with melanoma metastases and a positive pregnancy test J Am Acad Dermatol 41 802 803
11. UH Stenman H Alfthan K Hotakainen 2004 Human chorionic gonadotropin in cancer Clin Biochem 37 549 561
12. F Doi DJ Dorcas DDJ Chi BB Charuworn AJ Conrad J Russell DL Morton DSB Hoon 1996 Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma Int J Cancer 65 454 459
13. HF Acevedo JY Tong RJ Hartsock 1995 Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins Cancer 76 1467 1475
14. W Regelson 1995 Have we found the "definitive cancer biomarker"? The diagnostic and therapeutic implications of human chorionic gonadotropin-beta expression as a key to malignancy Cancer 76 1299 1301
15. JD Wolchok A Hoos S O'Day JS Weber O Hamid C Lebbé M Maio M Binder O Bohnsack G Nichol R Humphrey FS Hodi 2009 Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 5 7412 7420
16. JS Weber S O'Day W Urba J Powderly G Nichol M Yellin J Snively E Hersh 2008 Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 5950 5956
17. J Weber 2007 Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events Oncologist 12 864 872
18. JA Blansfield KE Beck K Tran JC Yang MS Hughes US Kammula RE Royal SL Topalian LR Haworth C Levy SA Rosenberg RM Sherry 2005 Cytotoxic T-lymphocyte associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer J Immunother 28 593 598
19. Chin K, Ibrahim R, Berman D, Yellin M, Lowy I, Lin R, Hoos A. Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA-4 therapy. Ann Oncol. 2008;19(Suppl. 8): 787.
20. Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol. 2008;26(Suppl.):abstract 9063.
21. Amin A, DePril V, Hamid O, Wolchok J, Maio M, Neyns B, Chin K, Ibrahim R, Hoos A, O'Day S. Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. J Clin Oncol. 2009;27:15s, suppl; abstr 9037.